Valneva SE
http://www.valneva.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Valneva SE
Valneva Hits New COVID-19 Jab Low With EC Contract Termination
Less than a year after signing a major advance purchase agreement to supply its inactivated COVID-19 jab to the EU, Valneva is faced with a termination that could hit its 2022 guidance.
Build Patient-Reported Outcomes Into Cancer Drug Dose Optimization, US FDA Says
In exploratory FDA analyses, PRO data appeared more sensitive at detecting an exposure-toxicity relationship for an oral small molecule cancer drug than clinician-reported data; Project Optimus representative dispels industry concerns that FDA wants firms to find the 'mythical' optimal dose.
Finance Watch: HilleVax, Belite Bio Launch First Two Biopharma IPOs In Q2
Also, Cytovia will go public via SPAC merger, Nkarta capitalized on its positive early NK cell therapy data with a $230m offering, and venture capital mega-rounds include $220m for Reify, $110m for Satellite Bio and $100m for OMass Therapeutics.
Valneva’s COVID-19 Vaccine Approved In UK While Talks Continue Over Scrapped Supply Deal
The MHRA has become the first regulatory agency worldwide to grant a marketing authorization for the inactivated whole virus COVID-19 vaccine, VLA2001.
Company Information
- Industry
- Contract Research, Toxicology Testing-CRO
-
Pharmaceuticals
- Drug Delivery
- Vaccines
-
Biotechnology
- Drug Discovery Tools
- Synthesis Technologies, Production Processes
- Transgenics
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- BliNK Biomedical SAS
- Crucell Sweden AB
- Iomai Corporation
- Intercell USA, Inc.
- Intercell AG, Vivalis